Administration of the immunosuppressive drug cyclosporine(CSA) after autologous peripheral blood stem cell transplantation(APBSCT) induces a systemic auto-immune syndrome resembling graft-versus-host disease(GVHD), th...Administration of the immunosuppressive drug cyclosporine(CSA) after autologous peripheral blood stem cell transplantation(APBSCT) induces a systemic auto-immune syndrome resembling graft-versus-host disease(GVHD), this syndrome termed autologous GVHD has significant antitumor activity, it can reduce the incidence of tumor relapse after APBSCT. The antitumor effect of this auto-aggression syndrome can be enhanced by the administration of γ-interferon(γ-IFN). Five consecutive patients who received APBSCT received therapy inducing autologous GVHD. Intravenous administration of CSA〔1 mg/(kg·d) for 28 days〕 was begin on the day of transplantation. γ-interferon(0.025 mg/m 2 qod) was administered sub-cutaneously from days 7 throngh 28 after transplatation. Results showed that four of five occured autologous GVHD-skin demage, five in control didn′t occur autologous GVHD. The relapse rate of the treated cases was 20%(1/5) versus 60%(3/5) of the control, and the median survival time of the treated cases was 20(4-30) months versus 10(2-20) months of the control. The data indicates that autologous GVHD results in low relapse rate of the patients rececving APBSCT.展开更多
文摘Administration of the immunosuppressive drug cyclosporine(CSA) after autologous peripheral blood stem cell transplantation(APBSCT) induces a systemic auto-immune syndrome resembling graft-versus-host disease(GVHD), this syndrome termed autologous GVHD has significant antitumor activity, it can reduce the incidence of tumor relapse after APBSCT. The antitumor effect of this auto-aggression syndrome can be enhanced by the administration of γ-interferon(γ-IFN). Five consecutive patients who received APBSCT received therapy inducing autologous GVHD. Intravenous administration of CSA〔1 mg/(kg·d) for 28 days〕 was begin on the day of transplantation. γ-interferon(0.025 mg/m 2 qod) was administered sub-cutaneously from days 7 throngh 28 after transplatation. Results showed that four of five occured autologous GVHD-skin demage, five in control didn′t occur autologous GVHD. The relapse rate of the treated cases was 20%(1/5) versus 60%(3/5) of the control, and the median survival time of the treated cases was 20(4-30) months versus 10(2-20) months of the control. The data indicates that autologous GVHD results in low relapse rate of the patients rececving APBSCT.
